---
title: Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia
date: '2024-06-03'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38828945/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240604181823&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In this phase 3 trial, crinecerfont was superior to placebo
  in reducing elevated androstenedione levels in pediatric participants with CAH and
  was also associated with a decrease in the glucocorticoid dose from supraphysiologic
  to physiologic levels while androstenedione control was maintained. (Funded by Neurocrine
  Biosciences; CAHtalyst Pediatric ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels in pediatric participants with CAH and was also associated with a decrease in the glucocorticoid dose from supraphysiologic to physiologic levels while androstenedione control was maintained. (Funded by Neurocrine Biosciences; CAHtalyst Pediatric ClinicalTrials.gov number, ...